Gene Therapy: A Paradigm Shift in Medicine

November 30, 2018

Gene therapy, the modification of genetic information in living cells to address a mutated gene, has the ability to dramatically change the way diseases are treated, or even cured. First conceptualized in the early 1970s, the seminal paper on the subject was published in Science by Theodore Friedmann and Richard Roblin, suggesting the great potential for gene therapy techniques in human genetic disease.

Spotlight

B. McLaughlin Associates, Inc (BMA)

BMA is a niche CRO that has been providing functional support in the areas of Data Management and Study Management for over 20 years. Our unique size, coupled with extensive therapeutic experience, allow us to consistently provide personalized, flexible services, and help clients reach critical clinical trial goals and timelines.

OTHER WHITEPAPERS
news image

PHARMACEUTICAL KEY ACCOUNT MANAGEMENT: HARNESSING SALES EXPERTISE TO DEVELOP UNIFIED STAKEHOLDER RELATIONSHIPS

whitePaper | November 25, 2022

To meet the needs of a growing range of external stakeholders, many life science companies are changing the ways that they disseminate information.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More
news image

Access to medicinal products

whitePaper | January 3, 2022

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs

Read More
news image

Navigating the Drug Development Pipeline: Expertise for Highly Potent API Product Handling

whitePaper | July 11, 2022

The expansion in the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) and complex active pharmaceutical ingredients (APIs) has grown tremendously as demands in healthcare to bring newer therapies to market quicker increase.

Read More
news image

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

Read More

Spotlight

B. McLaughlin Associates, Inc (BMA)

BMA is a niche CRO that has been providing functional support in the areas of Data Management and Study Management for over 20 years. Our unique size, coupled with extensive therapeutic experience, allow us to consistently provide personalized, flexible services, and help clients reach critical clinical trial goals and timelines.

Events